Neuralstem gets FDA OK

http://www.google.com/finance?chdnp=1&chdd=1&chds=1&chdv=1&chvs=maximized&chdeh=0&chdet=1253788357151&chddm=24633&chls=IntervalBasedLine&q=AMEX:CUR&ntsp=0

Neuralstem Inc (CUR.A) said U.S. health regulators allowed the stem-cell research company to start an early-stage human trial of its spinal cord stem cells in Lou Gehrig's disease, a fatal neuromuscular condition.

Shares of the company soared 63 percent to $3.05 in premarket trade. They closed at $1.87 Friday on the American Stock Exchange.

The trial, which will test the safety of the cells and the surgery procedure, will ultimately consist of 18 patients suffering from the disease, also known as amyotrophic lateral sclerosis (ALS), the company said.

Neuralstem has only received approval for the first stage of the trial that would consist of 12 patients who will receive stem cell injections in the lumbar area of the spinal cord.

ALS affects roughly 30,000 people in the United States, with about 7,000 new diagnoses per year, the company said in a statement

Stem Cell Stock News - Opexa (NASDAQ:OPXA) Announces Stem Cell Agreement with Leading Global Pharmaceutical Company
THE WOODLANDS, Texas- August 7 2009 -Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today announced that it has entered into an exclusive agreement with Novartis, one of the world’s largest pharmaceutical companies, for the further development of Opexa’s novel stem cell technology. This technology, which has generated preliminary data showing the potential to generate monocyte derived islet cells from peripheral blood mononuclear cells, was in early preclinical development at Opexa. Full story: http://www.investorideas.com/News/080709b.asp


Stem Cell Stock News - ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector
RANCHO CORDOVA, Calif., Aug. 7 2009 -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, announced today the introduction of the Res-Q(TM) 60 BMC ("Res-Q") System, an automated cell processing medical device for the concentration of bone marrow-derived stem cells at the point of care.

The Res-Q System processes bone marrow in minutes and delivers a high rate of stem cell recovery. The Res-Q System follows the late 2008 launch of the MXP(TM) MarrowXpress(TM) ("MXP") System, a laboratory device also used to collect stem cells from bone marrow.
Full Story: http://www.biotechindustrystocks.com/News/080709c.asp

Research More Stem Cell Stocks:
The global Biotech Stocks Directory at Biotechindustrystocks.com and Investorideas.com features a directory of Stem Cell Stocks, Medical Stocks, Life Sciences and Pharma Stocks for investors to research.
Visit the Biotech/Pharma Stock Directory: